Xerostomia
-
Subject Areas on Research
- A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer.
- Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.
- Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
- Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
- Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer.
- Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia.
- How should we measure and report radiotherapy-induced xerostomia?
- Hyposalivation and xerostomia in dentate older adults.
- Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
- Novel Manganese-Porphyrin Superoxide Dismutase-Mimetic Widens the Therapeutic Margin in a Preclinical Head and Neck Cancer Model.
- Oral manifestations of chronic graft-v-host disease.
- Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results.
- Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
- Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
- Re: Researchers make slow headway in managing dry mouth.
- Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials.
- Syndrome of inappropriate secretion of antidiuretic hormone in a patient with carcinoma of the nasopharynx.
- The double-blind in danger: untoward consequences of informed consent.
- The meaning of adolescents' eating experiences during bone marrow transplant recovery.
- The prevention and treatment of radiotherapy - induced xerostomia.
- Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial.